Roche’s MabTherea shot gets EU OK for chronic lymphocytic leukemia

ZURICH Drugmaker Roche has received European approval for an injectable form of antibody therapy MabThera for people with chronic lymphocytic leukemia, the company said on Tuesday.

The European Commission approved the injection for people with previously untreated and relapsed/refractory forms of the disease.

“MabThera SC provides patients with significantly faster treatment administration and the opportunity to enjoy more time outside the clinical setting compared to intravenous delivery of the medicine,” Chief Medical Officer Sandra Horning said.

(Reporting by Brenna Hughes Neghaiwi; Editing by Michael Shields)

comments powered by Disqus